Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics expects its FY24 GAAP basis total operating expenses to be between $150M and $170M. Excluding non-cash stock-based compensation, impairment, and depreciation/amortization expenses, non-GAAP operating expenses are projected to be between $125M and $145M.
August 06, 2024 | 9:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sangamo Therapeutics projects FY24 GAAP operating expenses of $150M-$170M and non-GAAP expenses of $125M-$145M, excluding certain non-cash expenses.
The projected operating expenses provide insight into the company's cost management for FY24. The non-GAAP figures, excluding non-cash expenses, offer a clearer view of operational efficiency. This information is crucial for investors but does not indicate a significant immediate impact on stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100